Insulin, Eight Specimens
Use
The Insulin Eight Specimens test is used to evaluate how the body's insulin levels respond over time after stimulation, typically by a drug or treatment like glucola. This is essential for assessing insulin secretion and resistance, often in the context of diagnosing or managing disorders like diabetes or insulinomas. The test involves sequential blood draws to monitor insulin response, helping clinicians tailor personalized treatment plans based on individual insulin dynamics.
Special Instructions
This panel requires multiple tubes drawn at specific time intervals, following an initial baseline measurement and subsequent patient treatment (e.g., a drug or glucola). Label each tube with the patient's name and corresponding time interval. It's important not to use this test without implementing the treatment phase. Additionally, patients should be asked about biotin supplementation, as high doses can interfere with results. Cease biotin intake at least 72 hours before sample collection.
Limitations
Results can be influenced by biotin supplementation, leading to false readings. Therefore, patients consuming high levels of biotin should stop intake three days prior to testing. Inaccurate specimen handling, such as failing to separate serum within 45 minutes, can impact the integrity of results. The specific reference intervals for insulin measurements beyond the baseline might not be established, requiring careful clinical interpretation.
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 20448-7
- 33816-0
- 33817-8
- 27832-5
- 27874-7
- 27875-4
- 27867-1
- 33818-6
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL per draw
Minimum Volume
Not provided
Collection Instructions
Submit 2 mL serum for both fasting and each post-dose interval. Separate serum from cells within 45 minutes of venipuncture. Label each tube with patient's name and the specific time interval.
Patient Preparation
Patients should cease biotin intake at least 72 hours prior to the collection of samples to avoid sample interference.